bluebird bio Announces First Patient Transplanted in Phase 1/2 Northstar Study for the Treatment of Beta-Thalassemia Read more about bluebird bio Announces First Patient Transplanted in Phase 1/2 Northstar Study for the Treatment of Beta-Thalassemia
bluebird bio Reports Fiscal Year End 2013 Financial Results Read more about bluebird bio Reports Fiscal Year End 2013 Financial Results
bluebird bio to Present at the Cowen and Company Health Care Conference Read more about bluebird bio to Present at the Cowen and Company Health Care Conference
bluebird bio to Present at the Leerink Global Healthcare Conference Read more about bluebird bio to Present at the Leerink Global Healthcare Conference
bluebird bio Appoints Dr James Mandell to its Board of Directors Read more about bluebird bio Appoints Dr James Mandell to its Board of Directors
bluebird bio to Present at the J.P.Morgan Healthcare Conference Read more about bluebird bio to Present at the J.P.Morgan Healthcare Conference
bluebird bio Joins the NASDAQ Biotechnology Index Read more about bluebird bio Joins the NASDAQ Biotechnology Index
bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia Read more about bluebird bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Study for the Treatment of Beta-Thalassemia and Sickle Cell Anemia
bluebird bio to Present at Deutsche Bank BioFEST Conference Read more about bluebird bio to Present at Deutsche Bank BioFEST Conference
bluebird bio Reports Fiscal Third Quarter 2013 Financial Results Read more about bluebird bio Reports Fiscal Third Quarter 2013 Financial Results